Dietary restrictions and drug interactions with monoamine oxidase inhibitors: An update

Journal of Clinical Psychiatry

Volumn 73, Issue SUPPL. 1, 2012, Pages 17-24

  Flockhart, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LINEZOLID; METHYLPHENIDATE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PLACEBO; RASAGILINE; SELEGILINE; SEROTONIN AGONIST; TRYPTOPHAN; TYRAMINE;

DEPRESSION; DIET RESTRICTION; DRUG CONTRAINDICATION; DRUG CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HYPERTENSIVE CRISIS; MAJOR DEPRESSION; PARKINSON DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SEROTONIN SYNDROME;

EID: 84864856634     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11096su1c.03     Document Type: Review

References (49)

1. Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141(1):89-101. doi:10.1016/j.psychres.205.07.012 PubMed
2. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression: a retrospective study. J Affect Disord. 2005;89(1-3):183-188. doi:10.1016/j.jad.205.06.01 PubMed
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Washington, DC: American Psychiatric Association; 2010. http://psychiatryonline. org/content.aspx?bookid=28§ionid=1667485. Accessed May 17, 2012.
4. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10): 855-870. PubMed
5. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7(4): 295-309. doi:10.1038/nrn183 PubMed
6. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010;77(12):859-882. doi:10.3949/cjm.7a.09103 PubMed
7. VanDenBerg CM. The transdermal delivery system of monoamine oxidase inhibitors. J Clin Psychiatry. 2012;73(suppl 1):25-30.
8. Rodriguez MA, Kumar SK, De Caro M. Hypertensive crisis. Cardiol Rev. 2010;18(2):102-107. doi:10.1097/CRD.0b013e3181c307b7 PubMed
9. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967; 113(497):349-365. doi:10.192/bjp.13.497.349 PubMed
10. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57(3):99-104. PubMed
11. McCabe-Sellers BJ, Staggs CG, Bogle ML. Tyramine in foods and monoamine oxidase inhibitor drugs: a crossroad where medicine, nutrition, pharmacy, and food industry converge. J Food Compost Anal. 2006;19(suppl):S58-S65. doi:10.1016/j.jfca.205.12.08
12. EMSAM (selegiline patch) [package insert]. Napa, CA: Dey Pharma LP; 2010. http://dailymed.nlm.nih.gov/dailymed/lookup. cfm?setid=b891bd9f-fdb8-4862-89c5- ecdd700398a3. Accessed May 17, 2012.
13. Nardil (phenelzine sulfate) [package insert]. New York, NY: Pfizer, Inc; 2011. http://dailymed.nlm.nih.gov/dailymed/lookup. cfm?setid=513a41d0-37d4-4355- 8a6d-a2c643bce6fa. Accessed May 17, 2012.
14. Shulman KI, Walker SE, MacKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397-402. doi:10.1097/04714-1989120-02 PubMed
15. Walker SE, Shulman KI, Tailor SA, et al. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol. 1996;16(5):383-388. doi:10.1097/04714-19610-07 PubMed
16. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60(3):191-193. doi:10.408/JCP. v60n0308 PubMed
17. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003;9(1):97-140. doi:10.1/j.1527-3458.203.tb0245.x PubMed
18. Naila A, Flint S, Fletcher G, et al. Control of biogenic amines in food: existing and emerging approaches. J Food Sci. 2010;75(7): R139-R150. doi:10.1/j.1750-3841.2010.0174.x PubMed
19. Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31(1):66-74. doi:10.1097/JCP.0b013e31820469ea PubMed
20. Jefferson JW. Who put the tyramine in Mrs. Murphy's fava bean [letter]? J Clin Psychiatry. 2008;69(8):1336-1337. doi:10.408/JCP.v69n0819b PubMed
21. Eldepryl (selegiline) [package insert]. Napa, CA: Dey Pharma LP; 2011. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=106429ad- 859a-4b29-babf-42cb85f7236e. Accessed May 17, 2012.
22. Marplan (isocarboxazid) [package insert]. Parsippany, NJ: Validus Pharmaceuticals, Inc; 2012. http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=ac387aa0-3f04-4865-a913-db6ed6f4fdc5. Accessed May 17, 2012.
23. Parnate (tranylcypromine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline LLC; 2012. http://dailymed.nlm.nih.gov/ dailymed/lookup.cfm? setid=b9f8ba41-3f86-4633-3e8e-fcf1cffa9756. Accessed May 17, 2012.
24. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42(11):1578-1583. doi:10.1086/503839 PubMed
25. Laine K, Anttila M, Helminen A, et al. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Br J Clin Pharmacol. 1999;47(3): 249-254. doi:10.1046/j.1365-2125.19.0891.x PubMed
26. Stahl MS. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press; 2008.
27. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6): 705-713. PubMed
28. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109 PubMed
29. Sternback H. Serotonin syndrome: how to avoid, identify, and treat. J Fam Pract Online. 2003;2(5). http://www.jfponline.com/Pages. asp?AID=636#2. Accessed May 16, 2012.
30. Rapaport MH. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry. 2007;68(suppl 8):42-46. PubMed
31. Robinson DS. Transdermal selegiline: a new-generation MAOI. Prim Psychiatry. 2006;13(5):33-35.
32. Jessen L, Kovalick LJ, Azzaro AJ. The selegiline transdermal system (EMSAM): a therapeutic option for the treatment of major depressive disorder. P T. 2008;33(4):212-246. PubMed
33. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993;342(8884):1419. doi:10.1016/0140-6736(93)9274-N PubMed
34. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(suppl 18):12-17. PubMed
35. Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome [letter]. J Clin Psychopharmacol. 1997;17(1): 66-67. doi:10.1097/04714-197020-02 PubMed
36. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64(2): 113-127. doi:10.107/BF01245973 PubMed
37. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869-1875. doi:10.176/api.ajp.159.1.1869 PubMed
38. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64(2):208-214. doi:10.408/JCP.v64n0216 PubMed
39. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26(6):579-586. doi:10.1097/01.jcp.0239794.37073.70 PubMed
40. Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354-1361. doi:10.408/JCP.v67n0905 PubMed
41. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3): 226-247. doi:10.1016/S0893-13X(98)075-X PubMed
42. Silverstone T. Moclobemide: placebo-controlled trials. Int Clin Psychopharmacol. 1993;7(3-4):133-136. doi:10.1097/04850-1930730-02 PubMed
43. Papakostas GI, Fava M. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry. 2006;51(12):783-790. PubMed
44. AZILECT (rasagiline mesylate) [package insert]. Kansas City, MO: TEVA Neuroscience, Inc; 2012. http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=a40d0e73-3f9f-4b01-979d-402c9cdaeb60. Accessed May 17, 2012.
45. Rascol O, Brooks DJ, Melamed E, et al, for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-954. doi:10.1016/S0140-6736(05)71083-7 PubMed
46. Perry PJ, Alexander B. Rational use of antidepressants. Prim Care. 1987;14(4):773-783. PubMed
47. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67(2):133-138. doi:10.1016/j.biopsych.209.08.029 PubMed
48. Lawrence S. Diagnostics investors think positive. Nat Biotechnol. 2006;24(8):884. doi:10.1038/nbt0806-84 PubMed
49. Gerretsen P, Müller DJ, Tiwari A, et al. The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci. 2009;11(4):363-376. PubMed